Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer (Q47932115)

6 February 2018

title

Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer (English)

1 reference

6 February 2018

author name string

Dah-Shyong Yu

1

1 reference

6 February 2018

Chi-Feng Lee

2

1 reference

6 February 2018

Dar-Shih Hsieh

3

1 reference

6 February 2018

Sun-Yran Chang

4

1 reference

6 February 2018

language of work or name

English

0 references

publication date

1 March 2004

1 reference

6 February 2018

published in

Urology

1 reference

6 February 2018

volume

63

1 reference

6 February 2018

issue

3

1 reference

6 February 2018

page(s)

596-601

1 reference

6 February 2018

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

BCG immunotherapy of bladder cancer: 20 years on.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Requirement of a thymus dependent immune response for BCG-mediated antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Pharmacotherapy of bladder cancer--practice and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.039

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2003.09.039

1 reference

6 February 2018

1 reference

6 February 2018